.avif)
Amicus Therapeutics Email Format
Biotechnology Research
・
501-1,000 employees
・
Princeton, NJ, USA
Amicus Therapeutics is a biotechnology company focused on developing therapies for rare genetic diseases, now part of BioMarin Pharmaceutical Inc.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@amicusrx.com
Company Overview
Industry
Biotechnology Research
Founded
2002
Headquarters
Princeton, NJ, USA
Revenue
$500M-$1B
FUNDING Stage
Acquired
Website
Key Executives
Bradley Campbell (President and Chief Executive Officer), Simon Harford (Chief Financial Officer), Pat O'Sullivan (Chief Technical Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Amicus Therapeutics?
Amicus Therapeutics uses the firstinitiallast format on amicusrx.com, so Jane Smith would be jsmith@amicusrx.com.
What approved medicines does Amicus Therapeutics currently offer patients?
Amicus Therapeutics has two FDA-approved treatments: Galafold (migalastat) for Fabry disease and the combination therapy Pombiliti (cipaglucosidase alfa-atga) plus Opfolda (miglustat) for Pompe disease.
Which rare diseases is Amicus Therapeutics actively researching beyond its approved products?
Beyond Fabry and Pompe disease, Amicus Therapeutics added Focal Segmental Glomerulosclerosis (FSGS), a serious rare kidney disorder, to its U.S. pipeline in 2025 as an investigational oral medicine. There are currently no approved therapies for FSGS.
Who leads Amicus Therapeutics as its top executive?
Bradley Campbell serves as President and Chief Executive Officer of Amicus Therapeutics, headquartered in Princeton, NJ. Simon Harford is the Chief Financial Officer and Pat O'Sullivan serves as Chief Technical Operations Officer.
How can I find and verify the contact details for a specific person at Amicus Therapeutics?
Since Amicus Therapeutics follows the firstinitiallast format on amicusrx.com, you can build a likely address from any name. A tool like Clay can help verify those addresses or enrich a prospect list with confirmed Amicus Therapeutics contacts at its 625-person team.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating